3.9 Review

Regulatory T Cell in Stroke: A New Paradigm for Immune Regulation

Journal

CLINICAL & DEVELOPMENTAL IMMUNOLOGY
Volume -, Issue -, Pages -

Publisher

HINDAWI LTD
DOI: 10.1155/2013/689827

Keywords

-

Categories

Funding

  1. NIH [NS060936]
  2. Research Fund for the Doctoral Program of Higher Education of China [20120101120030]
  3. Zhejiang Provincial Natural Science Foundation of China [LY13H090002]
  4. Health Bureau of Zhejiang Province [2013KYA088]

Ask authors/readers for more resources

Stroke is a common, debilitating trauma that has an incompletely elucidated pathophysiology and lacks an effective therapy. FoxP3(+)CD25(+)CD4(+) regulatory T cells (Tregs) suppress a variety of normal physiological and pathological immune responses via several pathways, such as inhibitory cytokine secretion, direct cytolysis induction, and antigen-presenting cell functional modulation. FoxP3(+)CD25(+)CD4(+) Tregs are involved in a variety of central nervous system diseases and injuries, including axonal injury, neurodegenerative diseases, and stroke. Specifically, FoxP3(+)CD25(+)CD4(+) Tregs exert neuroprotective effects in acute experimental stroke models. These beneficial effects, however, are difficult to elucidate. In this review, we summarized evidence of FoxP3(+)CD25(+)CD4(+) Tregs as potentially important immunomodulators in stroke pathogenesis and highlight further investigations for possible immunotherapeutic strategies by modulating the quantity and/or functional effects of FoxP3(+)CD25(+)CD4(+) Tregs in stroke patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available